ScreenerHero
ROVILaboratorios Farmaceuticos Rovi, S.A.
BME · ES · Healthcare · Drug Manufacturers - Specialty & Generic · rovi.es
59.75EUR-0.58%Mkt Cap: 3.32B $P/E: 16.51

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, B…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap3.32B $
Enterprise Value3.33B $
Revenue (TTM)840.27M $
Gross Profit524.66M $
Net Income (TTM)152.65M $
Revenue/Share16.43 USD
Last Price59.75 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINES0157261019
Valuation
P/E (Trailing)16.51
P/E (Forward)17.74
PEG1.26
EV/EBITDA17.39
EV/Revenue3.96
P/S3.96
P/B4.37
EPS (TTM)3.62
EPS (Forward)3.38
52W Range
53.1020% of range86.70
52W High86.70 EUR
52W Low53.10 EUR
Profitability
Gross Margin64.92%
Oper. Margin9.42%
EBITDA Margin22.76%
Profit Margin18.89%
ROE21.14%
ROA14.70%
Growth
Revenue Growth20.00%
Earnings Growth246.70%
Cash Flow & Leverage
Operating CF203.35M $
CapEx (TTM)73.71M $
FCF Margin21.67%
FCF Yield5.48%
Net Debt-22.15M $
Net Debt/EBITDA-0.12
Balance Sheet
Debt/Equity0.18
Current Ratio2.05
Quick Ratio1.04
Book Value/Sh13.70 EUR
Cash/Share2.504 EUR
Dividends
Fwd Div Rate0.9600 EUR
Trail. Div Rate0.9590 EUR
Div. Yield1.61%
5Y Avg Yield1.65%
Payout Ratio25.83%
Ex-Div DateJul 13, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)74.36 EUR
Upside (mean)+24.4%
Target Range64.20 EUR – 83.00 EUR
€64.20+24.4% to mean€83.00
# Analysts9
Ownership
Shares Out.51.14M
Float16.20M
Insiders68.20%
Institutions17.75%
Technical
SMA 5057.63 (+3.7%)
SMA 20067.01 (-10.8%)
Beta0.23
S&P 52W Chg18.16%
Avg Vol (30d)89.89K
Avg Vol (10d)101.87K
Technical Indicators
RSI (14)64.5
MACD0.3322
MACD Signal0.1899
MACD Hist.+0.1423
BB Upper60.10 EUR
BB Middle58.69 EUR
BB Lower57.28 EUR
BB Width4.81%
ATR (14)1.146 EUR
Vol Ratio (20d)1.64x